KAM
SIOX

Kazazian Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Kazazian Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,915
Closed -$76K – 95
2018
Q3 		$76K Hold
3,915
– – 0.07% 87
2018
Q2 		$71K Buy
+3,915
New +$57.7K 0.07% 84

Other funds holding SIOX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kazazian Asset Management's SIOX Position: Q4 2018 in Review

Kazazian Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 3,915 shares — an estimated $76K sold.

Kazazian Asset Management first reported a position in SIOX in Q2 2018 and held it in 2 quarters. The position peaked at $76K in Q3 2018. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

  • Kazazian Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 3,915 Sio Gene Therapies Inc. Common Stock shares in Q4 2018, an estimated $76K.
  • Kazazian Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Kazazian Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $76K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.